Skip to main content
Premium Trial:

Request an Annual Quote

Shifts at Pfizer

Pfizer is closing a research and development site in the UK at Sandwich, Kent, notes In the Pipeline's Derek Lowe. About 2,400 people work at the site and Pfizer says that it hopes to transfer a few those positions to other sites. "Although the company says that perhaps several hundred may find positions elsewhere, this is a major blow to drug discovery operations in the UK," Lowe says. The BBC adds that Pfizer manufacturing operations in Sandwich were shuttered in 2007.

The BBC also says that the closing is part of Pfizer's reorganization of its R&D operations and Ed Silverman at Pharmalot adds that, in the US, Pfizer is moving some of its R&D operations from Groton, Connecticut, to Cambridge, Massachusetts.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.